Abstract
Madrigal Pharmaceuticals will report third-quarter 2026 results on November 3, 2026 Pre-Mkt, with the market looking for approximately 404.26 million US dollars in revenue and adjusted EPS of -0.88 alongside continued top-line momentum from its core product franchise.Market Forecast
Consensus anticipates Madrigal Pharmaceuticals to deliver about 404.26 million US dollars in third-quarter revenue, up 63.47% year over year, with adjusted EPS around -0.88 implying a 57.83% year-over-year improvement and EBIT near -25.76 million US dollars indicating a 51.23% year-over-year improvement. The company’s core commercial franchise remains the central driver, with expectations anchored to sustained prescription growth; the prior quarter’s revenue base of 364.25 million US dollars sets a high bar but indicates strong run-rate heading into the period. Main business highlight and outlook: the Products segment is expected to continue benefiting from broadening utilization and payer uptake, with prescriptions and patient counts remaining the key near-term indicators. Most promising segment: core product sales reached 364.25 million US dollars last quarter, up 71.17% year over year, and remain the largest lever for incremental revenue and operating leverage over the next several quarters.Last Quarter Review
Madrigal Pharmaceuticals reported revenue of 364.25 million US dollars in the previous quarter, with gross profit margin of 89.02%, GAAP net profit attributable to the parent company of -57.94 million US dollars, net profit margin of -15.91%, and adjusted EPS of -1.99, reflecting a 4.74% year-over-year decline. A key highlight was better-than-expected revenue and EPS versus market estimates, paired with a 38.62% sequential improvement in net profit. Main business update: the Products segment contributed essentially all of the company’s 364.25 million US dollars of revenue and grew 71.17% year over year, underscoring healthy commercial execution.Current Quarter Outlook
Main business: Products franchise execution and quarterly drivers
The principal focus this quarter is on sustaining the commercial trajectory of the company’s flagship product line, which delivered 364.25 million US dollars in revenue last quarter and a gross profit margin of 89.02%. Given the forecast for 404.26 million US dollars in third-quarter revenue, management and investors will be watching the cadence of new patient starts and persistence trends to validate the implied sequential growth. Gross-to-net dynamics and payer coverage breadth are likely to influence realized pricing and margin, particularly as formulary adoption and patient assistance programs scale with broader use. Operating discipline will matter, as the company seeks to translate robust gross margin into improving operating results; the consensus forecast of -25.76 million US dollars in EBIT represents a meaningful year-over-year improvement consistent with scaling benefits. In the near term, channel inventory and shipment timing could introduce quarter-to-quarter variability, but the underlying demand trend remains the key determinant for whether consensus revenue and loss-per-share improvements materialize as expected.Most promising business: Core product expansion and adjacent pipeline initiatives
The strongest growth optionality continues to stem from expanding the core product’s reach across appropriate patient populations and care settings. The prior quarter’s report cited strong adoption metrics, highlighted by substantial year-over-year revenue growth of 71.17% in the Products segment, and by the end of June 2026, in-treatment patients surpassed 49,000. This scale provides a foundation for continued sequential revenue growth if prescription trends extend into the current quarter. At the same time, reported collaboration activities in RNA-based programs signal a longer-term pipeline strategy that complements the lead therapy, potentially broadening the future addressable opportunity and extending the product lifecycle. While such programs are not expected to contribute materially to this quarter’s financials, they can influence sentiment by demonstrating a path to diversified growth beyond the current commercial base.Key stock price swing factors this quarter
This quarter’s stock reaction will likely hinge on three quantitative signposts: revenue outturn relative to the 404.26 million US dollars consensus, the trajectory of adjusted EPS versus the -0.88 expectation, and the sustainability of high-80s gross margin levels. If realized revenue growth aligns with the 63.47% year-over-year forecast and adjusted EPS shows the expected 57.83% improvement, sentiment should benefit from visible operating leverage despite continued investment. Conversely, any evidence of slowing prescription growth, softer-than-expected gross-to-net realization, or elevated operating expense growth could temper the anticipated year-over-year improvements in EBIT and EPS. Beyond the P&L, investors will monitor qualitative commentary on payer dynamics, prescriber breadth, and patient adherence, as these factors shape the durability of revenue and margin trends across subsequent quarters.Analyst Opinions
Bullish views constitute the clear majority among the recent opinions collected, with three Buy ratings versus zero bearish calls, while one notable institution maintained a Neutral stance. Barclays reiterated a Buy rating with a 962.00 US dollars price target, citing continued confidence in top-line expansion supported by the core product’s adoption momentum and the visibility into near-term revenue scaling. Truist maintained a Buy rating, anchoring its case on durable sales growth and improving operating efficiency as the commercial footprint matures; its prior commentary and target framework reflect conviction that quarterly loss-per-share figures will continue to narrow as revenue scales. Citigroup initiated at Buy with a 725.00 US dollars price target and emphasized the alignment of consensus expectations with prescription trend data and the path toward improved EBIT, paralleling the 51.23% year-over-year improvement implied in current-quarter forecasts. Bank of America maintained a Neutral rating at a 533.00 US dollars target, pointing to a balance of strong revenue execution against the ongoing investment required to support commercialization; however, this stance does not offset the numerical predominance of bullish ratings in the period reviewed.The key pillar across bullish analyses is that consensus for the third quarter—404.26 million US dollars of revenue and adjusted EPS of -0.88—appears supported by recent quarterly run-rate and commercial indicators shared over the summer. Bulls also highlight that last quarter’s 89.02% gross margin demonstrates the capacity for substantial contribution margin, which can leverage fixed costs as volumes scale, reflected in the forecast for improved EBIT. They anticipate that near-term operating momentum, if coupled with continued payer expansion and steady patient additions, can deliver sequential revenue growth alongside narrowing losses, aligning with the 63.47% and 57.83% year-over-year improvements embedded in revenue and adjusted EPS expectations. Collectively, these views underscore a constructive setup into the print, contingent on confirmation that script growth and realized pricing remain consistent with the step-up implied by consensus.
Comments